Form 4: Alto Neuroscience Director Receives Stock Options

Alto Neuroscience, Inc. director Gwill York was granted 5,243 stock options as part of the company's non-employee director compensation policy.

Summary

• Director Gwill York of Alto Neuroscience, Inc. was granted 5,243 stock options.
• The stock options have an exercise price of $16.59 per share.
• The grant date for these options was January 2, 2026, and they are set to expire on January 1, 2036.
• This equity grant was issued in lieu of $62,000 in cash retainer fees.
• The options will vest quarterly throughout 2026, specifically 1,311 shares on March 31, 2026, 1,311 shares on June 30, 2026, 1,310 shares on September 30, 2026, and 1,311 shares on December 31, 2026, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The filing reflects a standard corporate governance practice of compensating a director with equity, which is generally viewed positively for aligning interests, but it is a routine disclosure rather than a significant positive or negative event for the company's operational or financial performance.

Positives

• Aligns director incentives with long-term shareholder interests through equity compensation.
• Utilizes stock options in lieu of cash retainer fees, potentially preserving company cash flow.

Negatives

• Potential for minor future dilution for existing shareholders if the options are exercised.

Risks

• The ultimate value of the stock options is dependent on the future stock performance of Alto Neuroscience, Inc.
• Vesting of the options is subject to the reporting person's continuous service through each vesting date, meaning the director must remain with the company to fully realize the benefit.

Future Outlook

The stock options granted to Director Gwill York are subject to a vesting schedule throughout 2026, contingent upon continuous service, aligning future compensation with company performance and encouraging long-term commitment.

Industry Context

Equity compensation for non-employee directors is a standard practice across many industries, particularly in biotechnology and emerging growth companies. This approach aligns director interests with long-term shareholder value and can help conserve cash, which is often critical for companies in development stages.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors in lieu of cash retainer fees is a common compensation strategy, comparable to practices at similar-stage biotechnology companies, which often use equity to attract and retain talent while managing cash burn.
• The vesting schedule, typically over one year for annual grants, is standard for director compensation, ensuring continued engagement and alignment with company performance over time.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience potential minor dilution if options are exercised, but benefit from aligned director incentives and potentially improved long-term company performance.
• Director (Gwill York): Receives equity compensation, aligning personal financial interests with the company's long-term success and providing a non-cash form of remuneration.

Next Steps

• Gwill York's continued service through the specified vesting dates to fully realize the option grant.
• Potential future exercise of the stock options by Gwill York, if the stock price is favorable, before the expiration date.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Stock Options, Director Compensation, Equity Grant, Gwill York